In addition, it has been reported that NA-1 does not interfere with the thrombolytic activity of tPA or TNK [10] and that a D-amino acid modified NA-1 (D-Tat-L-2B9c), unlike the unmodified NA-1, retains its neuroprotective efficacy when co-administered with alteplase in a rat embolic stroke model [8]. This evidence concerns the gene TAT and stroke disorder.